Skip to main content

Adicet Bio to Present at Upcoming Investor Conferences

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in September.

Details of the events are as follows:

H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022, New York, New York

  • An on-demand presentation given by Chen Schor, President & CEO will be available beginning Monday, September 12, 2022 at 7:00 A.M. ET

Jefferies Cell and Genetic Medicine Summit, September 29-30, 2022, New York, New York

  • Chen Schor, President & CEO, will present a corporate overview on Friday, September 30, 2022, at 8:00 A.M. ET.

The live audio webcast of the presentations can be accessed on the Investors section of Adicet Bio’s website at An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.